Natco Pharma’s marketing partner BPI obtains FDA approval for new drug

By Nikita Chaurasia  | Date: 2021-03-10

Natco Pharma’s marketing partner BPI obtains FDA approval for new drug

Breckenridge Pharmaceutical Inc. (BPI), a marketing partner of Natco Pharma, has reportedly received U.S. Food and Drug Administration (USFDA) approval for its Abbreviated New Drug Application of Everolimus drug tablets.

The drug is basically a generic version of Afinitor and is primarily used for breast cancer treatment, as well as for treating other types of cancer. Sources confirmed that BPI is planning to launch tablets of 7.5 mg, 5 mg, and 2.5 mg strengths in the upcoming weeks.

The company will reportedly launch its 10 mg strength drugs after a licensing agreement and settlement with the owner of the Afinitor brand. A representative from Natco Pharma commented that the launch will be announced at a later date.

For those unaware, Breckenridge Pharmaceutical Inc. is a subsidiary of Japan-based Towa Pharmaceutical Co. Ltd. The company is headquartered in Berlin, Connecticut, and manufactures, distributes as well as markets over 82 pharmaceutical drugs in the U.S.

It has more than 40 Abbreviated New Drug Applications (ANDA) approved by the Food and Drug Administration and manufactures drugs in several categories including capsules, tablets, liquids, ophthalmics, transdermal patches, powders, nasal sprays, and injectable products.

BPI has partnered with manufacturers from across the world and aims to provide generic pharmaceuticals that are affordable and cost-effective to U.S. patients.

Recently, another Hyderabad-based drug maker, MSN Group, which also has a marketing partnership with BPI, announced that it had received final approval from USDA for its ANDA for Asenapine Sublingual Tablets.

MSN had earlier received final approval for 10 mg and 2.5 mg strengths of the same drug. The product will be launched by its marketing partner Breckenridge Pharmaceutical. The approved product is a generic version of Saphris and is employed for the treatment of bipolar disorder and schizophrenia.

According to MSN, Asenapine had recorded annual sales of USD 239 million during the year ending in September 2020.

Source Credits –

https://www.thehindu.com/business/natco-pharma-marketing-partner-bpi-gets-usfda-nod-for-anti-cancer-drug/article34022425.ece

 

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More >>

More News By Nikita Chaurasia

Pacific Island pushes Japan to delay wastewater release from Fukushima

Pacific Island pushes Japan to delay wastewater release from Fukushima

By Nikita Chaurasia

Pacific Island nations have reportedly pushed Japan to postpone the release of Fukushima nuclear power plant wastewater due to concerns that it may pollute fishing grounds. An appeal was made on Wednesday when Japan announced that treated sewage f...

Activist groups take Danone to court over excessive use of plastics

Activist groups take Danone to court over excessive use of plastics

By Nikita Chaurasia

Danone, the French bottled water and yogurt firm, is reportedly being sued in court by three environmental activists’ groups for failing to cut its plastic footprint significantly. According to the groups, the maker of Evian and Volvic miner...

Bosch expands security with dashcams designed for rideshare drivers

Bosch expands security with dashcams designed for rideshare drivers

By Nikita Chaurasia

Bosch, the German technology company, has reportedly expanded its security footprint in the ridesharing market with the launch of its latest security dashcams. At CES 2023, Las Vegas, the German tech firm unveiled a new integrated smart camera on ...

Australia: PM Albanese denies potential $450M payout to Rio Tinto

Australia: PM Albanese denies potential $450M payout to Rio Tinto

By Nikita Chaurasia

Australia's Prime Minister Anthony Albanese has reportedly denied rumors that Rio Tinto and its partners could receive a $450 million settlement for the Gladstone power station, which would bring the total compensation for the coal price limit to...

UK: Firms still struggle with post-Brexit trading and red tape

UK: Firms still struggle with post-Brexit trading and red tape

By Nikita Chaurasia

Businesses in the UK are still reportedly grappling after two years following the beginning of post-Brexit trading, as suggested by a new report. According to the British Chambers of Commerce (BCC), firms are still battling increased red tape and ...